Sarepta Therapeutics to Present at Two Upcoming Investor Conferences

June 5, 2018 at 8:30 AM EDT

CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today announced that management will present at the following upcoming investor conferences:

  • Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 8:40 a.m. PT. The fireside chat will be held at the Terranea Resort in Rancho Palos Verdes, California.
     
  • JMP Securities Life Science Conference on Wednesday, June 20, 2018 at 9:30 a.m. ET. The fireside chat will be held at the St. Regis New York Hotel in New York.

The presentations will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates. For more information, please visit: www.sarepta.com.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com.We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Media and Investors:

Sarepta Therapeutics, Inc.

Ian Estepan, 617-274-4052

iestepan@sarepta.com

or

W2O Group

Brian Reid, 212-257-6725

breid@w2ogroup.com

 

Primary Logo

 

Source: Sarepta Therapeutics, Inc.